ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. The company is headquartered in Leiden, the Netherlands.
| Revenue (TTM) | $13.64M |
| Gross Profit (TTM) | $13.64M |
| EBITDA | $-45.36M |
| Operating Margin | -671.00% |
| Return on Equity | -78.10% |
| Return on Assets | -23.10% |
| Revenue/Share (TTM) | $0.13 |
| Book Value | $0.55 |
| Price-to-Book | 3.74 |
| Price-to-Sales (TTM) | 12.05 |
| EV/Revenue | 5.6 |
| EV/EBITDA | -2.10 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -57.10% |
| Shares Outstanding | $105.36M |
| Float | $64.35M |
| % Insiders | 17.66% |
| % Institutions | 48.91% |
Volatility is currently contracting